IGY Presentation Jan 2010 NML WPG

BEYOND ANTIBIOTICS -
TREATING VIRUSES & BACTERIA PATHOGENS WITH

SPECIFIC ANTIBIODIES - AND ELIMINATING THE SIDE
EFFECTS IN THE PROCESS.
JANUARY 26TH - NATIONAL MICROBIOLOGY LABORATORY

SAFE HARBOUR STATEMENTS
The information in this presentation is being made available to you and a limited number of other prospective investors on a confidential
basis, solely for the purpose of your consideration of an investment in securities under a securities purchase agreement, and such
information may not be used for any other purpose.
The information contained herein has been obtained from IGY Immune Technologies and Life Sciences Inc. (the “Company”) and from
sources believed by the Company to be reliable. The Company makes no representations or warranties, express or implied, as to the
accuracy or completeness of this information. The Company expressly disclaims any and all liability from any untrue statements or
omissions, which may be contained in this presentation or any other written or oral communication transmitted or made available to a
prospective investor. Only those particular representations made in a securities purchase agreement shall have any legal effect.
Certain statements in this presentation, such as those concerning the Company’s business strategy, products, revenues and capital
requirements, and other statements regarding matters that are not historical facts, and the Company’s financial projections included herein,
are “forward-looking” statements (as defined in the securities act of 1933). Because such forward-looking statements include
risk and uncertainties, actual results may differ materially from those expressed in or implied by such forward-looking statements.
During the course of your evaluation, all inquiries and other communications are to be made only to employees or representatives of the
Company. Accordingly, you agree not to directly or indirectly discuss with, or offer to, any third party a participation in a possible transaction
or any other form of joint investment or acquisition by you and such third party without The Company’s prior written consent.
IGY Immune Technologies & Life Sciences Inc.

PRESENTATION OVERVIEW
Overview
What We Do
Our Mission
The Trillion Dollar Health and Wellness Market
Building Immune Systems and Treating Specific World Health Problems
The Technology
Market Segments:
Medicines
Functional Foods
Agribusiness & Packaged Consumer Meat Producers
Cosmeceuticals
Corporate Structure
Strategic Timeline
Leverage Through Partnerships
Financial Forecasts
Financing Objectives
Management Team, Consultants, Advisory Board, Board Of Directors

WHAT WE DO
Our proprietary technology and processes makes it possible

to create health products to strengthen and supplement your
natural immune system against certain types of bacterial, viral
and autoimmune ailments.
IGY Immune Technologies and Life Sciences specializes in the extraction of

polyclonal antibodies, a type of antibody that are derived from chicken eggs for use
as nutraceuticals and pharmaceuticals for human and animal consumption.
Immunoglobulins are powerful antibodies produced in healthy humans and other

animals to fight infections and prevent disease. Egg yolks contain immunoglobulin
IgY, the functional equivalent of immunoglobulin IgG which makes up 75% of the
immunoglobulin found in healthy human plasma.

OUR MISSION
IgY Immune Technologies and Life Sciences Inc. is in the business of designing specific antibodies through natural
sources and purifying them through its proprietary extraction methods. By introducing specific antibodies to the
animal kingdom, we have the ability to prevent disease, save lives and reduce our dependence on antibiotics.
By improving the body’s natural immune system, like never before, we can improve the lives of millions suffering
from viral, bacterial, and autoimmune diseases.
By preventing the spread of disease, we can save hundreds of billions in valuable tax resources; allowing
governments to redirect their resources into other areas of science, to lower the costs of healthcare systems
around the world and ultimately, bring IgY medicine to the developing world.
By arming veterinary science with improved methods to farm our agriculture and aquaculture industries, we will
create a stronger food network and at the same time, a safer drinking water system by reducing it’s over use of
antibiotic drugs.
By extending these same specific antibodies to our family pets, they can live longer, healthier lives for everyone
to enjoy.
By putting into effect the knowledge of immunologists and microbiologists around the world, our scope of
science to be discovered is incredible.
By achieving all of this, our stakeholders will be pioneers in medical science and earn a valuable share in our
financial successes.
The Cure is in the Prevention. IgY for Life.

THE TRILLION DOLLAR HEALTH & WELLNESS MARKET
THE MARKET OPPORTUNITY
 Public health awareness continues to shift towards disease

prevention.
 Boosting immune systems will become an increasingly
important focus as our population base ages.
 Dietary supplements and vitamins, already used extensively,
don't contain the antibodies needed to fight off or prevent
disease.

THE TRILLION DOLLAR HEALTH & WELLNESS MARKET
“The biggest story of 2008 is the accelerating pace of the formulation

of nutraceuticals into functional foods. Beverages and dairy products
are the leading delivery vehicles but consumers appetite for more
natural and clinically demonstrated healthy ingredients in their food
has become a mainstream driving force for new product development
and product line extension.”
-Nutraceutical World, State of the Industry Review (Dec. 2008)

BUILDING THE IMMUNE SYSTEM AND TREATING WORLD HEALTH PROBLEMS
80 YEARS OF ANTIBIOTICS
“In his 1945 Nobel Prize address,

Alexander Fleming warned that it
was easy to produce microbes
resistant to his discovery, penicillin.
Simply expose them to concentrations
of the drug was insufficient to kill
them.”
John Hopkins Magazine, John Hopkins University

Alexander Fleming
Discovered Penicillin, 1928

Viral Bacteria
Autoimmune
•World health concerns are our concerns. More than ever before, viruses
spread at alarmingly fast rates due to global trade and travel.

•36,000 U.S. deaths and 200,000 hospitalizations attributed to influenza

each year. Direct and indirect cots of the average flu season amount to
approximately $10 billion. The World Bank estimated that a severe
influenza pandemic would cost the U.S. more than 600 Billion dollars,
potentially leading to a major global recession.

June 24, 2009
Here is the spread of Swine Influenza on a live basis. This map clearly shows
that we have a major health concern on our hands as this new pathogen is
spreading quickly in what is normally the off season for influenza.

August 3, 2009
• More than 70 countries are now reporting cases of human infection.

Because of global trade, which we are all dependent upon, there are no ‘safe’
zones from the effects of a new pandemic.

“I suffer no illusions that this will be an

easy process. It will be hard. But I also
know that nearly a century after Teddy
Roosevelt first called for reform, the cost of
our health care has weighed down our
economy and the conscience of our nation
long enough. So let there be no doubt;
health care reform cannot wait, it must
not wait, and it will not wait another year.”
- President Barack Obama, February 2009.
“Under the proposed Preservation of Antibiotics for Medical Treatment Act, or PAMTA, newly-developed
antibiotics couldn’t be given to farm animals unless they were sick. The casual use of already-established
drugs would be restricted.”
- Brandon Keim, Wired Magazine, July 21, 2009

Focusing in the immune system is

a natural evolution in fight against
diseases. Medical science is
recognizing the importance of
strengthening innate immune
system and reducing reliance on
antibiotics.

THE TECHNOLOGY
Breakthrough
IGY’s ground-breaking technology opens

the wide doorway to a whole new
science.

THE TECHNOLOGY
THE PROCESS
Antibody Extraction
IGY Immune Technologies & Life Sciences Inc
High Resolution Yolk Byproducts IG Antibodies

(Patented)

THE TECHNOLOGY
ANTIBODY YIELD FROM HENS
 A laying hen can produce approximately 300 eggs annually and the volume
of one egg yolk is approximately 15 ml.
 This could supply close to 100g of antibody per hen per year.
 Each Egg contains approximately 3-5mg IgY per ml of yolk (70-100mg of

total IgY antibody depending upon the size of the egg)
 Of this total and depending on the concentration level required for

commercial effectiveness, our technology can generate as little as10% or as
much as 75% antibody against a specific antigen.

THE TECHNOLOGY
ADVANTAGES OF ANTIBODIES FROM EGG YOLKS OVER MAMMALIAN ANTIBODIES

a. A single egg contains as much antibody as an average bleed from a rabbit. In addition,
egg collection is simple and noninvasive. Eggs are generally laid on a daily basis,
whereas a rabbit may only be bled once every 2-3 weeks.
b. Chickens require only a one month immunization regimen to obtain high titers of
polyclonal antibody. To ensure a rabbit is producing high titers of antibody, the
immunization procedure requires up to 2-3 months.
c. Similar amounts of antigen are required to immunize chickens and rabbits, but daily egg
collection occurs over a month and titers generally remain high during this period. A
rabbit may be bled only once every 2-3 weeks and the amount of antibody contained in
the sera is equivalent to the amount of antibody in a single egg.
d. Because the phylogenetic distance between birds and mammals is great, chickens are
very useful for producing antibodies against conserved mammalian proteins. Typically, 1-
5% of rabbit sera will be comprised of antibodies against a specific mammalian antigen.
About 2-10% of a chicken egg yolk is comprised of antigen-specific antibodies. In
addition, very highly conserved mammalian proteins sometimes fail to elicit an immune
response in rabbits but antibodies against these proteins are often successfully produced
in the avian system.

THE TECHNOLOGY
IgY Works on Both Viral and Bacteria Infections
Viral infections include: Bacterial infections include:
 All colds and flu  Strep throat

 Most coughs  Urinary tract infections
 Most sore throats, and  Most ear infections
 Usually involve several  Some sinus infections, and
parts of the body  Are usually localized at a
single point in the body

THE PROCESS OF MAKING IGY – ON A COMMERCIAL SCALE
 160,000
eggs per
day.
 ONE KILO
of 50% Pure
IgY is
produced by
350,000
birds
laying
10,500 eggs
per month.

Eggs are
broken at a
Canadian
Food
Inspected
egg station,
and the
unused
portion is put
back into the
food
production.

… then mixed
with water and
centrifuged to
create a Water
Soluble
Fraction,
containing the
desired IgY.

•The prototype
facility was over
$10 million in
design and
installation.
•Capable of
producing up to
2,000 kg per
month of IgY.

ISOLATION OF IGY FROM EGG YOLK
Results: SDS-PAGE
IgY
Rm rt+w1 w2 el

ISOLATION OF IGY FROM EGG YOLK
Results: Size exclusion chromatography
IgY
App. 60 % purity

THE TECHNOLOGY
EFFECTIVENESS OF IGY FOR SALMONELLA

THE TECHNOLOGY
COMPETITIVE ADVANTAGES
 Higher concentration of IgY (traditional 5% purity vs. 25% or >)

 Fats are removed
 No Cholesterol
 Pharmaceutical grade
 Tasteless and odorless
 Can be “designed” for a variety of applications
 Can be used in an aerosol
 No competitive technology
 Comprehensive patents on intellectual property
.

THE TECHNOLOGY
INTELLECTUAL PROPERTY PROTECTION
Our Company’s value lies in our ability

to continuously generate new IP
protection for IgY. We are regularly
adding new patents to our existing
portfolio.
Patent approvals are sought

internationally for ingredients and
processes and for products that are
developed.
We have chosen not patent certain key

elements of our process for added
protection.

THE TECHNOLOGY
MANUFACTURING & PRODUCTION
 Control over egg supply chain

 Eggs are the most economical and practical solution as chickens lay eggs
regularly, so there is a continual source of antibody
 Agreements secured with suppliers
 economical and practical solution deal to the leftover egg byproduct

MARKET SEGMENTS
COMMERCIAL APPLICATIONS
Our commercial applications fall across 4 primary sectors which means we can grow
our product base and revenue streams against any cyclical variations.

MARKET SEGMENTS: MEDICINES
IGY SPECIFIC - CLOSTRIDIUM DIFFICILE (C.DIFFICLE)
Ig(Y) specific for Clostridium Difficile Bacteria.
Under development with Dr. Michelle Alfa, University of

Manitoba and St. Boniface Hospital
Expected combined phase I and II trials to be completed

within 24 months, and a marketable pharmaceutical ready
for 2012
Expected to generate over a Billion dollars of revenue in

North America alone.
Dr. Alfa has already proven the viability of generating the

antigens from the eggs, the problem remained commercial
ability to produce an Ig(Y) Specific, which has now been
solved.

MARKET SEGMENTS: MEDICINES
CLOSTRIDIUM DIFFICILE (C.DIFFICLE)

LETHAL HOSPITAL BUG CASES ROCKET, UNITED KINGDOM
Potentially lethal cases of C. Difficile “rocketed” from 1990s to 2004
Cases had increased from 1,000 in 1990 to over 35,000 in 2003
44,488 cases of C. Difficile in > 65 year olds in 2004.
Good new stats here on C. Dif. with 7,000 cases per day, and 300
mortalities per day.
$51.5 million in health care costs, per day in the United States. That is
$18.8 Billion per year in costs. This just for C. Diff. not to mention MSRA.
A single occurrence of CDI adds about $3,700 to a hospital bill and can
mean three or more additional nights in the hospital.
BBC News. http://news.bbc.co.uk/2/hi/health/4186834.stm

MARKET SEGMENTS: FUNCTIONAL FOODS

PHARMA FOODS INTERNATIONAL CO., LTD
Multi-Million dollar letter of intent signed December 25th,

2008.
Pharma Foods markets a variety of Ig(Y) products.
Majority of Asians and Mexicans suffer from HP bacteria.
Second part of agreement to produce H5N1 (avian flu)

antibody.
Current processes provide approximately 5% purity of H. Pylori

IGY. Our process provides 50-75% purity of H. Pylori IGY.
Discussions with Pharma Company in China to produce a H.Pylori

pharmaceutical.

http://www.pharmafoods.co.jp

MARKET SEGMENTS: AGRIBUSINESS AND PACKAGED CONSUMER MEATS

MARKET SEGMENTS: COSMECEUTICALS
THE COSMECEUTICALS MARKET
 The cosmeceuticals market is forecasted to reach $21 billon by

2012
 Sales of natural body care products are thriving with 14%
growth in 2007 and annual compound growth of 57% since
2004
 Skin care, hair care and colour cosmetic cosmeceuticals showed
an overall 25% gain in the retail sector between 2003 and 2007

A natural and a safe alternate to Antibiotic

Treatment for Acne
Our Acne Product is an antibody tailored skin treatment. The antibody

specifically targets the primary acne bacteria called Propionibacterium acnes or
P. Acnes for short. Our acne treatment inactivates P. Acnes and thereby
removes the major cause of skin inflammation and disease. Without P. Acnes
the skin will heal and new lesions will not occur.
Before After
Treatment Treatment

The IGY Skincare Program is a complete

system of three products
1. Cleansing Mousse : Contains Natural Oceanic Clay, Herbs and Vitamin E to protect and
maintain the skin’s health while natural emulsifiers and scrubbing beads remove makeup
and soils effectively.
2. Natural Oceanic Clay mask with IgY: Anti-Acne Clay Mask with IgY helps combat
blemishes and blackheads in a double action through the combined forces of our Natural
Oceanic Clay and APA - IgY.
3. Moisturizing Cream with IgY: This anti-acne moisturizing cream is formulated as a

treatment for prevention of acne skin infections caused by Propionibacterium acne. Our
unique antibody treatment – APA-IgY (Anti Propionibacterium Acnes-IgY) penetrates the
skin and destroys the Propionibacterium Acne-bacteria that is common among all forms of
acne, and prevents the appearing of blackheads and blemishes. Panthenol and Sunflower
Oil moisturizes the skin. This beneficial formula completes the treatment of acne while
maintaining the healthy condition of the skin.

INFOMERCIAL STRATEGY
Proactiv annual worldwide sales are

about $850 million, 70 percent of which
are in the United States.
“Right now, we own acne,” said Greg

Renker, a chief executive of Guthy-
Renker, the direct-response television
company that sells Proactiv“
New York Times, October 2007

STRATEGIC TIMELINE

LEVERAGE RESOURCES THROUGH PARTNERSHIPS
 FedNor
 Provincial Health Care
Ministries
 National Research
Counsel, IRAP program
 Ironwood Clay Company
 University of Manitoba
 St. Boniface Research
Centre

THE OPPORTUNITY LIES IN OUR LEADERSHIP
 While the current budget is set for cosmeceutical and

nutraceutical applications, the opportunity for the National
Microbiology Lab lies in a joint effort to create the first
pharmaceutical IgY product.
 A C. difficile IgY Specific remains our top priority.
 Much of the phase I & II clinical work has been completed
by the SBRC.
 Steps to move forward include acquiring a government
approved vaccine for C. difficile, producing a test sample of
IgY Specific C. difficile, completing the requirements for
human testing.

THE OPPORTUNITY LIES IN OUR LEADERSHIP
ELISA C.difficile
0.8
0.7
0.6
0.5 Sigma
A(4 IRI 27067
05
nm 0.4 IRI 07067
)
IRI 27067 Eggcellent Extract
blank (diluent)
0.3
3% gelatin coated vs 27067 extract
3% gelatin coated vs 27067
0.2
0.1
0
62.5 125 250 500 1000 2000 4000 8000
[IgY] (ng/mL)

IGY C. DIFFICILE SPECIFIC – SAVE LIVES & MONEY
 Currently, 300 people per day die as a result of C. difficile

related causes in the USA everyday.
 The cost to the US health-care system is $51.5 million per
day.
 The average cost of a stay in a Canadian hospital is $1,350,
escalating to $2,500 per day in an isolation room.
 We estimate that at 75% of the patient load in a health
care facility taking C. difficile IgY Specific antibodies, at
$3.50 per day would save roughly $16 billion in health care
costs in North America and 120,000 lives annually.

IMAGINE THE POSSIBILITIES
 Candida albicans
 Rotavirus
 Streptococcus mutans
 Listeria monocytogenes
 Parvovirus
 Celiac and colitis
 Cystic fibrosis
 Staphylococcal enterotoxin B
 As a tool in proteomics

MANAGEMENT TEAM
Terry N. Dyck President, CEO
Sharad Mistry Chief Financial Officer
John Mason Chief of Research
David Mason Chief of Operations

CONSULTANTS
Dr. Stu Richie Canadian Poultry Consultants Ltd.
Roger Upton, President Ironwood Clay Company
Ian Cooke Facilities Engineer
Ameann DeJohn Ameann Solutions, CA
Bob Jones, Principle Scientia Advisors
John Henderson, President Brain Box Communications

ADVISORY BOARD
Ron Bayne President of GloBayne
Dr. John Webb Director of Science, Maple Leaf Foods
Ken Boshcoff Governmental Affairs
Dr. Frank Mauro Periodontist
Dr. Sheetal Sapra Dermatology
Dr. Keith Ly Dermatology
Dr. Jeanette Jacknin Dermatology

LEGAL TEAM
Michael Strickland, corporate affairs Bust & Partners, Thunder Bay, ON
Jay Lefton, securities law Ogilvy Renault, Toronto
Stephen Burri, Intellectual Property Miller Thomson, Vancouver
John Cameron, BDO Dunwoody Auditors, Thunder Bay

BOARD OF DIRECTORS
Terry N. Dyck, President and CEO
Kevin Nephin
Dr. Brian Scott
Rashid Ahmed
pending

QUESTIONS AND ANSWERS
A New Beginning…
Boosting the Immune System,
Prevention is the Cure.

IGY Presentation Jan 2010 NML WPG

Încărcat de

Informații document

Descriere originală:

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

IGY Presentation Jan 2010 NML WPG

Încărcat de

Drepturi de autor:

Formate disponibile

BEYOND ANTIBIOTICS -

TREATING VIRUSES & BACTERIA PATHOGENS WITH

JANUARY 26TH - NATIONAL MICROBIOLOGY LABORATORY

IGY Immune Technologies & Life Sciences Inc.

IGY Immune Technologies & Life Sciences Inc.

Our proprietary technology and processes makes it possible

IGY Immune Technologies and Life Sciences specializes in the extraction of

Immunoglobulins are powerful antibodies produced in healthy humans and other

IGY Immune Technologies & Life Sciences Inc.

The Cure is in the Prevention. IgY for Life.

IGY Immune Technologies & Life Sciences Inc.

THE MARKET OPPORTUNITY

 Public health awareness continues to shift towards disease

IGY Immune Technologies & Life Sciences Inc.

“The biggest story of 2008 is the accelerating pace of the formulation

IGY Immune Technologies & Life Sciences Inc.

“In his 1945 Nobel Prize address,

John Hopkins Magazine, John Hopkins University

IGY Immune Technologies & Life Sciences Inc.

IGY Immune Technologies & Life Sciences Inc.

•36,000 U.S. deaths and 200,000 hospitalizations attributed to influenza

IGY Immune Technologies & Life Sciences Inc.

June 24, 2009

IGY Immune Technologies & Life Sciences Inc.

• More than 70 countries are now reporting cases of human infection.

IGY Immune Technologies & Life Sciences Inc.

“I suffer no illusions that this will be an

- President Barack Obama, February 2009.

- Brandon Keim, Wired Magazine, July 21, 2009

IGY Immune Technologies & Life Sciences Inc.

Focusing in the immune system is

IGY Immune Technologies & Life Sciences Inc.

IGY’s ground-breaking technology opens

IGY Immune Technologies & Life Sciences Inc.

High Resolution Yolk Byproducts IG Antibodies

IGY Immune Technologies & Life Sciences Inc.

 Each Egg contains approximately 3-5mg IgY per ml of yolk (70-100mg of

 Of this total and depending on the concentration level required for

IGY Immune Technologies & Life Sciences Inc.

ADVANTAGES OF ANTIBODIES FROM EGG YOLKS OVER MAMMALIAN ANTIBODIES

IGY Immune Technologies & Life Sciences Inc.

IgY Works on Both Viral and Bacteria Infections

Viral infections include: Bacterial infections include:

 All colds and flu  Strep throat

IGY Immune Technologies & Life Sciences Inc.

IGY Immune Technologies & Life Sciences Inc.

IGY Immune Technologies & Life Sciences Inc.

IGY Immune Technologies & Life Sciences Inc.

IGY Immune Technologies & Life Sciences Inc.

IGY Immune Technologies & Life Sciences Inc.

IGY Immune Technologies & Life Sciences Inc.

EFFECTIVENESS OF IGY FOR SALMONELLA

IGY Immune Technologies & Life Sciences Inc.

 Higher concentration of IgY (traditional 5% purity vs. 25% or >)

IGY Immune Technologies & Life Sciences Inc.

INTELLECTUAL PROPERTY PROTECTION

Our Company’s value lies in our ability

Patent approvals are sought

We have chosen not patent certain key

IGY Immune Technologies & Life Sciences Inc.

MANUFACTURING & PRODUCTION

 Control over egg supply chain

IGY Immune Technologies & Life Sciences Inc.